For many, GLP-1 receptor agonists like Ozempic and Wegovy represent a significant medical advance in weight management. However, alongside the positive changes on the scale, some individuals are experiencing an unexpected side effect: alterations in facial appearance. Often referred to as “Ozempic Face,” this phenomenon is drawing attention from dermatologists and aesthetic practitioners.
The term “Ozempic Face” isn’t a formal medical diagnosis, but rather a descriptor that emerged on social media and in clinical practice to characterize visible facial changes resulting from rapid weight loss, explains Vienna-based dermatologist Barbara Franz. “It doesn’t just disappear fat from the belly or hips, but also the subcutaneous fat in the face,” Franz stated. This facial fat is crucial for maintaining a youthful, full appearance.
The loss of this subcutaneous fat can lead to a narrower visage, more sunken cheeks, more prominent tear troughs, deepened nasolabial folds (lines from the nose to the mouth), and more defined marionette lines (lines from the mouth to the chin). The jawline may also lose its definition. The initial change often observed is a loss of volume, according to Franz.
Compounding the issue is the natural loss of skin elasticity that occurs with age. As supporting fatty tissue diminishes, the skin can become more relaxed, particularly in individuals aged 35 and older, where natural collagen production is already declining. This can exacerbate the appearance of wrinkles and sagging.
The increasing prevalence of GLP-1 therapies is leading to a corresponding rise in patients seeking cosmetic interventions to address volume loss. Dermatologists are adapting their treatment strategies to address these concerns. Hyaluronic acid fillers are frequently used to restore volume in the midface, providing relatively quick and visible results. Biostimulators, which encourage the body’s own collagen production, offer a more gradual and natural-looking improvement. In select cases, autologous fat transfer – using a patient’s own fat – may be considered.
Skin tightening procedures, such as radiofrequency, ultrasound, or laser treatments, can also be employed to improve skin quality. However, Franz cautions against overcorrection, emphasizing the importance of a “holistic, reserved approach.” Excessive filler can create an unnatural appearance.
While treatments can address the effects of “Ozempic Face,” prevention is also key. A moderate and gradual approach to weight loss can minimize abrupt volume losses. Adequate protein intake supports muscle maintenance and skin structure, while strength training can further stabilize tissues. A proactive dermatological consultation before significant weight loss may also be beneficial, allowing for early intervention to mitigate potential changes.
“GLP-1 medications are medically effective and useful when indicated – but any significant change in weight affects the face,” Franz summarizes. The phenomenon highlights the importance of considering the holistic impact of weight loss, extending beyond the number on the scale to encompass changes in facial structure and skin health.
The changes observed aren’t limited to those using Ozempic (semaglutide) or Wegovy. Rapid weight loss from any cause – including bariatric surgery or significant lifestyle changes – can lead to similar facial alterations. However, medications like semaglutide and tirzepatide are often associated with particularly rapid weight loss, potentially intensifying these effects.
According to the Cleveland Clinic, “Ozempic face” is characterized by gauntness, sunken cheeks, new wrinkles and loose skin on the face and neck. It’s important to remember that this isn’t a direct side effect of the medication itself, but rather a consequence of the rapid weight loss it can induce.
The skin changes associated with rapid weight loss, sometimes referred to as “Ozempic butt” as well, can include loose, sagging areas. These changes are a result of the skin not having time to adjust to the reduced underlying fat volume.
